| Address:
|
300 GEORGE STREET
|
| City: |
NEW HAVEN |
|
State: |
CT |
|
Zip Code: |
06511 |
| Telephone: |
203-624-7000 |
|
Description of Business
|
Primary SIC Code:
2834 |
| (As filed with the SEC)
|
|
|
We are a biopharmaceutical company focused on the discovery, development and
commercialization of innovative treatments for infectious diseases. Within the
anti-infective market, we are currently concentrating on the development of
antivirals for the treatment of chronic hepatitis C and the development of
antibacterials for the treatment of resistant bacterial infections. We are
currently focusing our efforts on developing three drug candidates for the
treatment of chronic hepatitis C (HCV): ACH-1625, a protease inhibitor for the
treatment of chronic hepatitis C, currently being tested in an on-going phase
IIa clinical trial, ACH-2684, a pangenotypic protease inhibitor for which we
have completed preclinical testing, and ACH-2928, a NS5A inhibitor for which we
have completed preclinical testing. We also have developed ACH-1095, a NS4A
antagonist for the treatment of chronic hepatitis C, to which Gilead Sciences,
Inc., or Gilead, retains certain future development rights. ... More ... |
| Date |
12-mos
Rolling EPS |
Dividend |
P/E
Ratio |
| 09/2011 | -0.61 | NA | N/E | | 06/2011 | -0.61 | NA | N/E | | 03/2011 | -0.58 | NA | N/E | | 12/2010 | -0.57 | NA | N/E | | 09/2010 | -0.72 | NA | N/E | | 06/2010 | -0.72 | NA | N/E | | 03/2010 | -0.89 | NA | N/E | | 12/2009 | -0.98 | NA | N/E |
Key Financial Ratios and Statistics |
FYE:
12/31 |
| Profitability |
2010 |
Leverage |
2010 |
| Net Inc/Comm Equity | -0.09 | Total Liab/Total Assets | 0.13 | | Net Inc/Total Assets | -0.44 | Total Liab/Inv Cap | 0.15 | | Net Inc/Inv Cap | -0.48 | Total Liab/Comm Equity | 0.03 | | Pretax Inc/Net Sales | -10.46 | Interest Coverage Ratio | -88.72 | | Net Inc/Net Sales | -10.46 | Curr Debt/Equity | 0.01 | | Cash Flow/Net Sales | -9.81 | LTD/Equity | NA | | SG&A/NetSales | 2.96 | Total Debt/Equity | 0.01 |
| Asset Utilization
|
|
Liquidity |
|
| Net Receivables Turnover | 15.67 | Quick Ratio | 11.05 | | Inventory Turnover | NA | Current Ratio | 11.05 | | Inventory Day Sales | NA | Net Rec/Curr Assets | 0.00 | | Net Sales/Work Cap | 0.05 | Inv/Curr Assets | NA | | Net Sales/PP&E | 5.21 | | |
Income Statement (Millions) |
| |
9/30/2011
|
6/30/2011
|
3/31/2011
|
12/31/2010
|
|
Total Revenues(Net Sales)
|
0.06
|
0.06
|
0.07
|
2.01
|
|
Cost of Goods Sold
|
NA
|
NA
|
NA
|
NA
|
|
Selling & Admin Exps
|
1.92
|
2.44
|
2.22
|
2.16
|
|
Operating Income
|
-10.47
|
-11.28
|
-10.15
|
-6.25
|
|
Interest Exp
|
0.01
|
0.00
|
0.02
|
0.04
|
|
Pretax Income
|
-10.44
|
-11.25
|
-10.13
|
-6.24
|
|
Other Income
|
0.04
|
0.03
|
0.04
|
0.05
|
|
Net Income Bef Extraordinary ...
|
NA
|
NA
|
NA
|
NA
|
|
Net Income
|
-10.44
|
-11.25
|
-10.13
|
-6.24
|
|
Assets
|
9/30/2011
|
6/30/2011
|
3/31/2011
|
12/31/2010
|
|
Cash & Short Term Investments
|
65.14
|
99.58
|
46.41
|
55.20
|
|
Receivables - Total
|
0.09
|
0.36
|
0.09
|
0.25
|
|
Inventories - Total
|
NA
|
NA
|
NA
|
NA
|
|
Total Current Assets
|
67.27
|
101.85
|
49.25
|
57.50
|
|
Net Property, Plant & Equipment
|
1.06
|
0.83
|
0.41
|
0.47
|
|
Total Assets
|
93.36
|
102.83
|
49.94
|
58.24
|
|
Liabilities
|
|
|
|
|
|
Accounts Payable
|
8.27
|
7.90
|
6.36
|
4.73
|
|
Debt in Current Liabilities
|
0.14
|
0.14
|
0.00
|
0.47
|
|
Total Current Liabilities
|
8.41
|
8.04
|
6.36
|
5.20
|
|
Long-Term Debt
|
0.27
|
0.30
|
NA
|
0.00
|
|
Total Liabilities
|
11.16
|
10.83
|
8.84
|
7.69
|
|
Stockholder's Equity
|
|
|
|
|
|
Minority Interest
|
NA
|
NA
|
NA
|
NA
|
|
Preferred Stock
|
NA
|
NA
|
NA
|
0.00
|
|
Common Stock
|
0.07
|
0.07
|
0.06
|
0.06
|
|
Retained Earnings
|
-263.22
|
-252.78
|
-241.53
|
-231.39
|
|
Treasury Stock
|
NA
|
NA
|
NA
|
NA
|
|
Total Stockholders' Equity
|
82.20
|
92.00
|
41.10
|
50.54
|
|
Total Liabilities and Stockholders' Equity
|
93.36
|
102.83
|
49.94
|
58.24
|
Cash Flow Summary (Millions) |
|
Categories
|
9/30/2011
|
6/30/2011
|
3/31/2011
|
12/31/2010
|
|
Net Cash Provided by Operating Activities
|
-9.26
|
-8.17
|
-8.22
|
-5.74
|
|
Net Cash Provided by Investing Activities
|
-49.26
|
-0.54
|
12.02
|
4.49
|
|
Net Cash Provided by Financing Activities
|
-0.02
|
61.91
|
-0.45
|
-1.05
|
Annual Summary Data (Millions) |
| Year |
Sales |
Net
Income |
EPS |
| 12/2006 | 3.29 | -24.09 | -9.35 | | 12/2007 | 4.04 | -28.10 | -1.80 | | 12/2008 | 0.00 | -28.15 | -1.42 | | 12/2009 | -0.29 | -25.93 | -0.98 | | 12/2010 | 2.44 | -25.48 | -0.57 | | Growth Rates | -7.25 | -- | -- |
| Type |
Date(Q,M) |
No.
Owners |
Shares
Held (000s) |
%
Own |
| Institutional | 12/31/11 | 100 | 39,992 | 57.34 |
|
Report Date :
1/30/2012
 Copyright
2012, EDGAR Online, Inc. All
rights reserved. Replication or redistribution of EDGAR Online, Inc. content is
expressly prohibited without the prior written consent of EDGAR Online, Inc.
EDGAR Online, Inc. shall not be liable for any errors or delays in the content,
or for any actions taken in reliance thereon.
|
|
|